Clinical Trials Logo

Stage IV Cancer clinical trials

View clinical trials related to Stage IV Cancer.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT03475589 Recruiting - Stage IV Cancer Clinical Trials

Study on the Adverse Drug Reactions (ADRs) of Apatinib and Their Biomarker Correlations

Start date: February 26, 2018
Phase: Phase 4
Study type: Interventional

The tolerability of apatinib, an effective antiangiogenic agent, varies greatly in patients with stage IV cancer during treatment. This study will include patients with advanced (stage IV) gastric cancer, non-small-cell lung cancer (NSCLC), breast cancer or ovarian cancer, who will be administered apatinib treatment starting from 250 mg Qd and closely monitored for ADRs during the period of apatinib treatment. Meanwhile, relevant assay technologies will be used to precisely detect changes of various biomarkers in the patients treated by apatinib, with the aim of identifying biomarkers related to their prognosis and relevant complications so as to screen out the favored population, establish the drug's indication(s) and reduce relevant side effects.